David Lescuyer – Managing Director, Skyepharma, France
David Lescuyer, managing director of Skyepharma, a specialized CDMO, reflects on the past three years of the company as it transitioned from a drug delivery platform to a fully-fledged service…
Genfit is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology.
Conscious of the importance of strategically aligning our company with patient needs, our R&D efforts are focused on contributing to bringing new medicines to market for patients with serious diseases whose treatment options are limited or non-existent.Our rigorous drug discovery and development process, and our commitment to improving health through innovation, have resulted in the creation of a pipeline dedicated to areas where we can lead and make a significant impact.
Our lead pipeline product Elafibranor (GFT505) has recently completed a positive Phase 2b study in NASH (Non-Alcoholic Steato-Hepatitis) and is currently launching a Phase 3 study. This metabolism-related liver disease, which can progress to cirrhosis and even liver cancer, shows a dramatically increasing prevalence worldwide. Elafibranor represents a major hope for patients and their physicians, who currently have no efficient treatment for NASH.
In addition to Elafibranor, our R&D pipeline relies mainly on our world-renowned scientific expertise in gene regulation and nuclear receptors.
It is comprised of multiple drug candidate research programs targeting novel mechanisms of action including the inhibition of RORγ-t.
GENFIT Headquarters
Parc Eurasanté
885, Avenue Eugène Avinée
59120 Loos
France
+33 (0)3 20 16 40 00
David Lescuyer, managing director of Skyepharma, a specialized CDMO, reflects on the past three years of the company as it transitioned from a drug delivery platform to a fully-fledged service…
Dr Marc-Alexander Burmeister, president of B. Braun in France, shares the exciting changes to come for B. Braun globally and in France, and discusses the shifting environment of healthcare in…
Françoise Alliot-Launois, VP of the French League Against Rheumatism (AFLAR), discusses the issues around bone and joint infections in France, AFLAR’s work to help patients suffering from these diseases, and…
Finn Søndergaard, CEO of Intsel Chimos, shares the motivation behind the company’s two recent acquisitions of Diverchim and Centre Lab, and the new strategic opportunities to expand as a full-service…
Abbvie France’s Pierre-Claude Fumoleau outlines his strategic priorities for the affiliate, AbbVie’s unique corporate culture and ethos, and how he envisions upcoming regulatory reforms playing out in France. We…
Denis Delval, CEO of iconic French pharma firm LFB since December 2017, discusses his key priorities to build the new LFB. My vision is that we should be strong…
Biotest’s Olivier Samama outlines the changes that the takeover of the company has had on the French affiliate, the country’s plasma market and pricing policy. The product offering remains…
Edouard Bieth, managing director of Tillotts Pharma in France, discusses the opportunities and challenges of opening an affiliate in the country and the uniqueness of Tillotts’ specialization in gastrointestinal drugs.…
The healthcare and life sciences industries, as they become more advanced and complex, increasingly require government involvement to ensure clinical compliance, ethical behaviour and the well-being of the nation. The health sector is…
Arnaud Gobet, president of Innothera, discusses how the company balances its unique and diverse offering of medical devices, hygiene and protection products and pharmaceuticals, Innothera’s burgeoning international footprint and the…
Josephine Yang Comiskey, president of GSK France, gives insights into GSK’s corporate culture, portfolio and priorities in France. She also highlights the need for collaboration and a better dialogue between…
Pierre Banzet, CEO of French CDMO Groupe SYNERLAB, shares how the group has developed over the past three years and discloses his strategy for generating specialty production knowledge as well…
See our Cookie Privacy Policy Here
